Search Results

Aternium to Build First U.S. Heavy Water and High-Purity Hydrogen Production Facility in Delaware

Aternium announced on August 4 that it has selected Dover, Delaware, as the site for its first commercial heavy water and electrolytic hydrogen production facility. The company has reached a definitive sales agreement for a parcel within Garrison Oak Technical Park, with the transaction expected to close by mid-Q4 2026. The project will serve as Aternium's flagship production initiative in the United States, planned to produce heavy water (deuterium oxide) and high-purity hydrogen. According to company disclosures, the project is expected to bring at least $226 million in capital investment to Dover, create dozens of direct and supporting jobs, and generate hundreds of construction jobs during the build-out phase...

2026-08-05

South Korea Accelerates Safety Reviews of Long-Term Operating Nuclear Reactors and Advances Licensing of First Spent Fuel Dry Storage Facility

The Nuclear Safety and Security Commission (NSSC) of South Korea stated at its second-half work report meeting on August 4 that it will accelerate safety reviews of long-term operating nuclear reactors while simultaneously advancing regulatory efforts such as licensing systems for spent fuel dry storage facilities and small modular reactors. Under the plan, the NSSC will conduct safety inspections on nine reactors applying for continued operation, with review standards referencing newly built nuclear power plants and confirming safety margins in consideration of the characteristics of long-term unit operation. Among these, whether Kori Nuclear Power Plant Units 3 and 4 will be approved for continued operation in the second half of this year, and whether Hanbit Nuclear Power Plant Units 1 and 2 will be approved for continued operation in the first half of next year, are the near-term review priorities...

2026-08-05

BWXT to Sell Medical Business to Nordic Capital for Up to $800 Million

On August 3, BWX Technologies, Inc. announced that it has reached a definitive agreement to sell its medical business to healthcare investment company Nordic Capital. The transaction is valued at up to $800 million and includes BWXT Medical and the stable medical isotope business of Kinectrics. BWXT stated that the divestiture will help the company concentrate resources and capital to drive growth in its core nuclear national security business and commercial nuclear power market operations. The company believes these areas are its long-term strategic priorities. Under Nordic Capital's ownership, the medical business is expected to further expand its scale, enhance capabilities, and strengthen its position in the radiopharmaceutical field...

2026-08-04

Curium and Lantheus Reach Definitive Merger Agreement to Build a Global Integrated Radiopharmaceutical Theranostics Platform

On August 3, global radiopharmaceutical company Curium announced that it has entered into a definitive merger agreement with Lantheus Holdings, Inc. Under the agreement, Curium US Holdings LLC will merge with Lantheus through its wholly owned subsidiary, with a total consideration of up to $114.50 per share and a total transaction value of approximately $8 billion. Under the terms of the agreement, Curium US will acquire all outstanding shares of Lantheus at $102.50 per share in cash upon closing of the transaction. In addition, Lantheus shareholders will receive non-transferable contingent value rights, entitling them to up to $12.00 per share in additional cash payments if certain commercial milestones for Lantheus-related products are achieved by 2030...

2026-08-04

Czech Republic Leads EU Project to Assess Application of Commercial-Grade Items in VVER Nuclear Power Plants

The Czech State Office for Nuclear Safety (SÚJB) has launched a two-year EU project focused on assessment methodologies for the application of high-quality commercial-grade items in nuclear power plants equipped with VVER reactors. The project aims to establish a unified, expert-judgment-based evaluation process that provides methodological support for nuclear facilities when introducing relevant items, while ensuring that nuclear safety requirements are not compromised. As the nuclear power supply chain landscape evolves, certain plant-specific components may face the need to be replaced by commercial-grade products. In response, regulatory authorities need to establish clear rules to review the suitability, quality assurance, and safety implications of substitute items. The project will focus on evaluating...

2026-08-04

Antineutrinos Detected for the First Time in Spent Fuel Elements

Even after a nuclear reactor has been shut down, the radioactive fuel continues to emit a faint stream of antineutrinos. The Double Chooz collaboration, led by scientists from the Max Planck Institute for Nuclear Physics (MPIK), has succeeded for the first time in measuring this elusive signal, opening up new prospects for reactor monitoring, nuclear safety, and control procedures. The Double Chooz detector. Image credit: Double Chooz collaboration. The research team conducted these measurements at the Chooz nuclear power plant in northern France. The Double Chooz detector is located approximately 400 meters underground, in close proximity to two reactor cores. Inside, the detector contains more than 30 cubic meters of liquid scintillator material...

2026-08-04

UT-ORNL Recruits Radiopharmaceutical Scientist to Advance Integrated Cancer Diagnosis and Treatment

The University of Tennessee and Oak Ridge National Laboratory jointly announced that Dr. Carolyn Anderson has been appointed to the UT-ORNL Governor's Chair in Nuclear Medicine: Radiopharmaceutical Therapy. Anderson officially assumed the position on August 1, serving concurrently as a professor in the Department of Nuclear Engineering at the University of Tennessee, Knoxville, and as a researcher in the Isotope Science and Enrichment Directorate at Oak Ridge National Laboratory. She is an internationally renowned pioneer in the field of radiopharmaceutical science, having worked at institutions such as the University of Washington, the University of Pittsburgh, and the University of Missouri. Dr. Anderson's research focuses on developing compounds that can identify cancer earlier, assess treatment efficacy, and deliver radiation directly to tumors...

2026-08-04

DuChemBio Completes Supply Chain for Prostate Cancer Radiopharmaceutical

DuChemBio, a Korean radiopharmaceutical company, announced on August 4 that it has completed the supply chain for ProstaSeek (active ingredient: 18F-plotupolastat), a radiopharmaceutical for prostate cancer diagnosis, in the Yeongnam and Honam regions. The drug targets prostate-specific membrane antigen (PSMA), and all tertiary general hospitals in both regions that perform PET-CT scans and provide prostate cancer diagnosis and treatment have been included in its supply scope. According to data from the National Cancer Registry of the Korean Ministry of Health and Welfare, new prostate cancer cases reached 22,640 in 2023, accounting for 7.8% of all cancer cases and ranking sixth in male cancer incidence; with the increasing adoption of PSMA-targeted therapy, the demand for precise diagnosis before prostate cancer treatment is also growing rapidly.

2026-08-04

Study Shows Sustained Deuterium Fusion in Palladium and Titanium Metal Foils at Ultra-Low Energies

U.S. researchers have observed a low-energy deuterium fusion phenomenon in thin palladium and titanium metal foils: when the incident deuteron energy drops to levels where fusion reactions are generally expected to weaken significantly or even nearly cease, the reactions continue to occur. Experiments show that as incident energy decreases, the fusion rate does not continue to decline exponentially but instead enters a plateau region below approximately 2 keV. At the lowest detectable energy, the measured low-energy fusion rate exceeds predictions from isolated-nucleus models by more than 10^18 times. Image courtesy of Marina Light/University of California, Davis. The related research was conducted by teams at the University of California, Davis and Lawrence Berkeley National Laboratory...

2026-08-04

Ratio Therapeutics Completes $70 Million Series C Financing to Advance Clinical Development of Ac-225 Targeted Radiopharmaceuticals

Ratio Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company, recently announced the completion of a $70 million Series C financing round. The company stated that following this round, its cumulative total financing has exceeded $240 million. According to the announcement, this round saw participation from existing investors Duquesne Family Office and Bristol Myers Squibb, while also bringing in new investors such as Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. Ratio Therapeutics stated that the proceeds will be used to advance the clinical development of its targeted radiotherapeutic product pipeline and expand manufacturing infrastructure. The company plans to continue advancing the ATLAS study, which is evaluating its lead radiotherapeutic agent [Ac-2...

2026-08-03

Swiss PSI Ultracold Neutron Experiment Finds No Signs of "Mirror World" Oscillation

The Paul Scherrer Institute (PSI) in Switzerland announced on July 28 that its researchers detected approximately 25 billion neutrons in an ultracold neutron experiment and found no signs of neutrons spontaneously transforming into mirror neutrons. The results constrain, with high certainty, the theoretical possibility of neutrons disappearing into the so-called mirror world. The mirror world hypothesis posits that every elementary particle in the real world may have a corresponding mirror particle, such as mirror electrons, mirror protons, and mirror neutrons. Such particles interact extremely weakly with ordinary matter, potentially connecting primarily through gravity or rare oscillations of neutral particles, and have therefore also been considered as dark matter candidates...

2026-08-03

German Science and Humanities Council Supports German Participation in the LEGEND-1000 Neutrinoless Double Beta Decay Experiment

On July 27, 2026, the German Science and Humanities Council expressed its support for German participation in the LEGEND-1000 experiment. The project had previously passed scientific evaluation and was deemed significant for a broad research community in the fields of particle physics and nuclear physics. LEGEND-1000 is the next phase of the large-scale enriched germanium neutrinoless double β decay experiment, planned to be constructed by an international collaborative team at the underground laboratory of the Gran Sasso National Laboratory in Italy. German participating institutions include the Max Planck Institute for Nuclear Physics in Heidelberg and the Technical University of Munich, with project leaders being Professor Susanne Mertens and Professor Stefan Schönert, respectively. According to the project...

2026-08-03

Bolivia Advances Legislative Process for Peaceful Nuclear Technology Applications

EL ALTO, Bolivia, July 29 - The Bolivian Nuclear Energy Agency (ABEN) recently held working exchanges with relevant committees of the Plurinational Legislative Assembly to discuss the reactivation of related legislative agendas, focusing on the continued advancement of Bolivia's nuclear energy program and peaceful nuclear technology application projects. René Soria Sausedo, Executive Director of ABEN, stated that as the primary operating entity of Bolivia's nuclear program, ABEN bears the responsibility of driving the implementation of peaceful nuclear technology application projects. These efforts require modern legal instruments to define institutional mandates, technical standards, and the fundamental legal framework for project development. The parliamentary delegation, led by the President of the International Policy and Migration Protection Committee, visited ABEN facilities...

2026-08-03

DUNE Prototype Detector Undergoes 300 kV Pressure Test at CERN

The Deep Underground Neutrino Experiment (DUNE), an international collaborative project led by the Fermi National Accelerator Laboratory under the U.S. Department of Energy, is conducting pressure tests on the prototype detector ProtoDUNE at CERN's Neutrino Platform to verify the long-term stability of the relevant detection technology under extreme operating conditions. DUNE is designed as a large-scale neutrino research experiment aimed at studying the properties of neutrinos and their role in the evolution of the universe. The experiment will install large liquid argon time projection chamber detectors approximately one mile underground at the Sanford Underground Research Facility in South Dakota, USA. Once the detectors are filled with liquid argon and sealed, internal components will be difficult to access for extended periods...

2026-08-03

Russia's Vector Research Center Proposes Quantum Dots for Boron Delivery in Neutron Capture Therapy

Russia's Vector Research Center has proposed using quantum dots as targeted boron delivery systems in boron neutron capture therapy (BNCT) to explore more precise approaches to tumor treatment. Yuri Tumanov, the center's chief researcher, presented this research progress at a conference on engineering biology and biopharmaceuticals. Boron neutron capture therapy is a cancer treatment method that combines boron-containing drugs with neutron irradiation. The basic concept involves first allowing boron-containing drugs to accumulate in tumor cells, then subjecting the patient to neutron irradiation, which triggers a nuclear reaction that releases energy concentrated within boron-containing cancer cells, thereby destroying tumor cells. How to construct boron delivery systems that are low-toxicity, highly efficient, and capable of participating in targeted tumor destruction remains one of the key challenges in this field...

2026-08-01